companiesCompany
Betta Pharmaceuticals
aka 贝达药业
Betta made icotinib, the first cancer drug invented in China, and later ensartinib, the first Chinese ALK inhibitor to win FDA approval.
Overview
Icotinib (Conmana) approved 2011; ensartinib (Ensacove) approved in China 2020 and by the FDA in December 2024 for ALK-positive NSCLC through Xcovery; befotertinib (from InventisBio) approved 2023; the MCLA-129 EGFR x c-MET bispecific from Merus for China.
Headquarters
Hangzhou, CN
Scorecard
All companies#62of 680 companies, score 40
- approved products +12
- targets +4
- modalities +2
- regions +2
- registry trials +20
2 approved, 0 in phase 3, 0 earlier, 2 targets, 101 registry studies. Formula on the scorecards page.
Type
biotech · 300558.SZ
Stage
Public
Website
Founded
2003
ApprovedSmall-molecule first-generation EGFR TKI
Icotinib · Conmana
Icotinib, approved in 2011, was the first cancer drug invented and developed in China, and it showed that a domestic lung cancer pill could match a Western one head to head.
ApprovedSmall-molecule ALK TKI (second generation)
Ensartinib · Ensacove
A Chinese-developed ALK pill approved in the US in December 2024 for first-line ALK-positive lung cancer.
Pages like this
not linked directly; found by shared links- ProductGarsorasib
Shares InventisBio and the tag china.